ApexBio (1733) Monthly Revenue

Market: TWSE-listed · Industry: Biotech & Medical · 五鼎

ApexBio (1733) reported revenue of NT$133.9 million for Oct 2026, -13.9% year on year and -3.9% from the previous month. Revenue for Jan–Oct 2026 was NT$1.55 billion (-6.6% year on year).

In Oct 2026, it ranked No. 61 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$156.7 million24/10Nov 2024 NT$126.7 millionDec 2024 NT$170.5 millionJan 2025 NT$169.7 millionFeb 2025 NT$202.7 million25/02Mar 2025 NT$186.4 millionApr 2025 NT$187.3 millionMay 2025 NT$177.8 millionJun 2025 NT$144.9 million25/06Jul 2025 NT$109.2 millionAug 2025 NT$146.9 millionSep 2025 NT$181.1 millionOct 2025 NT$155.5 million25/10Nov 2025 NT$140.5 millionDec 2025 NT$143 millionJan 2026 NT$200.1 millionFeb 2026 NT$178.3 million26/02Mar 2026 NT$141.4 millionApr 2026 NT$151 millionMay 2026 NT$145.7 millionJun 2026 NT$174 million26/06Jul 2026 NT$142.6 millionAug 2026 NT$146.4 millionSep 2026 NT$139.4 millionOct 2026 NT$133.9 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$133.9 million-13.9%-3.9%
Sep 2026NT$139.4 million-23.0%-4.8%
Aug 2026NT$146.4 million-0.4%+2.7%
Jul 2026NT$142.6 million+30.5%-18.0%
Jun 2026NT$174 million+20.1%+19.4%
May 2026NT$145.7 million-18.1%-3.6%
Apr 2026NT$151 million-19.3%+6.8%
Mar 2026NT$141.4 million-24.1%-20.7%
Feb 2026NT$178.3 million-12.0%-10.9%
Jan 2026NT$200.1 million+17.9%+39.9%
Dec 2025NT$143 million-16.1%+1.8%
Nov 2025NT$140.5 million+10.9%-9.7%
Oct 2025NT$155.5 million-0.8%-14.1%
Sep 2025NT$181.1 million-2.9%+23.3%
Aug 2025NT$146.9 million-19.9%+34.5%
Jul 2025NT$109.2 million-21.9%-24.6%
Jun 2025NT$144.9 million-5.2%-18.5%
May 2025NT$177.8 million+22.4%-5.0%
Apr 2025NT$187.3 million+33.8%+0.5%
Mar 2025NT$186.4 million+43.7%-8.0%
Feb 2025NT$202.7 million+56.6%+19.4%
Jan 2025NT$169.7 million-11.4%-0.5%
Dec 2024NT$170.5 million+55.4%+34.6%
Nov 2024NT$126.7 million-23.8%-19.2%
Oct 2024NT$156.7 million+16.9%-15.9%

Jan–Oct 2026 cumulative: NT$1.55 billion (-6.6% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: ApexBio vs PEC / ApexBio vs Lotus Pharm / ApexBio vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16